Betahistine for the treatment of neurodegenerative diseases
Disclosed herein are method of treating neurodegenerative diseases, including Alzheimer's disease, with the anti-histaminic drug betahistine.
1. A method of treating a neurodegenerative disease, comprising administering to a subject in need thereof, a therapeutically effective amount of betahistine or a pharmaceutically acceptable salt thereof, wherein the neurodegenerative disease is Alzheimer's disease and wherein the betahistine or a pharmaceutically acceptable salt thereof is administered orally in an amount from 250-5,000 mg/week with a pharmaceutically acceptable carrier or excipients.
2. The method of claim 1 , wherein the betahistine or a pharmaceutically acceptable salt thereof is administered daily.
3. The method of claim 1 , wherein betahistine or a pharmaceutically acceptable salt thereof is administered at least once daily.
4. The method of claim 1 , wherein the betahistine or pharmaceutically acceptable salt thereof is administered in combination with one or more other therapeutics.
5. The method of claim 4 , wherein the other therapeutic comprises an acetylcholinesterase inhibitor or an NMDA receptor antagonist.